We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-1.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$150M
(-3.3%)
Cap. Flow
+$100M
Cap. Flow
% of AUM
2.31%
Top 10 Holdings %
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
19
Top Buys
| 1 |
Eli Lilly
LLY
|
+$183M |
| 2 |
argenx
ARGX
|
+$128M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$108M |
| 4 |
Johnson & Johnson
JNJ
|
+$97.3M |
| 5 |
Humana
HUM
|
+$95M |
Top Sells
| 1 |
Merck
MRK
|
+$194M |
| 2 |
Baxter International
BAX
|
+$149M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$146M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$115M |
| 5 |
AbbVie
ABBV
|
+$109M |
Sector Composition
| 1 | Healthcare | 95.35% |
| 2 | Financials | 0.54% |
| 3 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AstraZeneca
AZN
$261B
| $231M | 5.31% |
1,749,500
-100,500
| -5% | -$13.2M |
|
2
Vertex Pharmaceuticals
VRTX
$121B
| $223M | 5.13% |
793,000
+247,400
| +45% | +$66.2M |
|
|
3
argenx
ARGX
$54B
| $217M | 4.98% |
572,500
+396,500
| +225% | +$128M |
|
4
Elevance Health
ELV
$84.8B
| $213M | 4.89% |
441,000
+41,600
| +10% | +$20.6M |
|
5
Avantor
AVTR
$7.65B
| $207M | 4.75% |
6,652,700
+984,400
| +17% | +$30.7M |
|
|
6
Eli Lilly
LLY
$1.03T
| $198M | 4.54% |
+610,000
| New | +$183M |
|
|
7
Humana
HUM
$49B
| $193M | 4.43% |
412,300
+213,400
| +107% | +$95M |
|
8
United Therapeutics
UTHR
$22.6B
| $171M | 3.93% |
725,600
+6,654
| +0.9% | +$1.35M |
|
|
9
Johnson & Johnson
JNJ
$595B
| $160M | 3.67% |
900,200
+546,200
| +154% | +$97.3M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $148M | 3.4% |
1,856,900
+725,500
| +64% | +$68.7M |
|
11
Neurocrine Biosciences
NBIX
$17.3B
| $143M | 3.28% |
1,467,600
+307,600
| +27% | +$28.4M |
|
12
Arvinas
ARVN
$534M
| $141M | 3.24% |
3,355,623
+440,323
| +15% | +$22.1M |
|
|
13
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $139M | 3.2% |
1,875,000
+1,435,000
| +326% | +$108M |
|
14
McKesson
MCK
$93.2B
| $127M | 2.91% |
388,800
+199,300
| +105% | +$63.8M |
|
15
UnitedHealth
UNH
$380B
| $124M | 2.86% |
242,200
-17,400
| -7% | -$8.74M |
|
|
16
AbbVie
ABBV
$431B
| $116M | 2.65% |
755,000
-711,100
| -49% | -$109M |
|
17
Syndax Pharmaceuticals
SNDX
$2.08B
| $105M | 2.41% |
5,450,000
+626,600
| +13% | +$10.4M |
|
|
CTLT
18
DELISTED
CATALENT, INC.
CTLT
| $102M | 2.35% |
955,000
+173,000
| +22% | +$17.6M |
|
19
Zentalis Pharmaceuticals
ZNTL
$340M
| $101M | 2.31% |
3,585,881
+408,882
| +13% | +$10.8M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $97.3M | 2.23% |
550,000
+450,000
| +450% | +$64.8M |
|
21
Boston Scientific
BSX
$64B
| $94.1M | 2.16% |
2,525,000
+1,328,900
| +111% | +$54.1M |
|
22
Biogen
BIIB
$29.1B
| $89.8M | 2.06% |
440,566
+75,566
| +21% | +$15.4M |
|
23
Ultragenyx Pharmaceutical
RARE
$3.12B
| $88.3M | 2.03% |
1,479,500
+610,500
| +70% | +$37.6M |
|
24
Acadia Healthcare
ACHC
$2.97B
| $70M | 1.61% |
+1,035,000
| New | +$72.2M |
|
25
Intellia Therapeutics
NTLA
$1.82B
| $58.2M | 1.34% |
1,125,194
+735,119
| +188% | +$37.3M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH